首页> 外文OA文献 >Increasing Tumor Volume Is Predictive of Poor Overall and Progression-Free Survival: Secondary Analysis of the Radiation Therapy Oncology Group 93-11 Phase I-II Radiation Dose-Escalation Study In Patients With Inoperable Non-Small-Cell Lung Cancer
【2h】

Increasing Tumor Volume Is Predictive of Poor Overall and Progression-Free Survival: Secondary Analysis of the Radiation Therapy Oncology Group 93-11 Phase I-II Radiation Dose-Escalation Study In Patients With Inoperable Non-Small-Cell Lung Cancer

机译:增加肿瘤体积预测总体不良和无进展生存:放射治疗肿瘤学组93-11阶段I-II放射剂量 - 升级研究对不能手术的非小细胞肺癌患者的二次分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose Patients with non–small-cell lung cancer (NSCLC) in the Radiation Therapy Oncology Group (RTOG) 93-11 trial received radiation doses of 70.9, 77.4, 83.8, or 90.3 Gy. The locoregional control and survival rates were similar among the various dose levels.We investigated the effect of the gross tumor volume (GTV) on the outcome.Methods and Materials The GTV was defined as the sum of the volumes of the primary tumor and involved lymph nodes. The tumor response, median survival time (MST), and progression-free survival (PFS) were analyzed separately for smaller (≤45 cm3) vs. larger (u3e45 cm3) tumors.Results The distribution of the GTV was as follows: ≤45 cm3 in 79 (49%) and u3e45 cm3 in 82 (51%) of 161 patients. The median GTV was 47.3 cm3. N0 status and female gender were associated with better tumor responses. Patients with smaller (≤45 cm3) tumors achieved a longer MST and better PFS than did patients with larger (u3e45 cm3) tumors (29.7 vs. 13.3 months, p u3c 0.0001; and 15.8 vs. 8.3 months, p u3c 0.0001, respectively). Increasing the radiation dose had no effect on the MST or PFS. On multivariate analysis, only a smaller GTV was a significant prognostic factor for improved MST and PFS (hazard ratio [HR], 2.12, p = 0.0002; and HR, 2.0, p = 0.0002, respectively). The GTV as a continuous variable was also significantly associated with the MST and PFS (HR, 1.59, p u3c 0.0001; and HR, 1.39, p u3c 0.0001, respectively).Conclusions Radiation dose escalation up to 90.3 Gy did not result in improved MST or PFS. The tumor responses were greater in node-negative patients and women. An increasing GTV was strongly associated with decreased MST and PFS. Future radiotherapy trials patients might need to use stratification by tumor volume.Int. J. Radiation Oncology Biol. Physics, Volume 70, No. 2, pp. 385-390, 2008
机译:目的放射治疗肿瘤学组(RTOG)93-11试验中的非小细胞肺癌(NSCLC)患者接受了70.9、77.4、83.8或90.3 Gy的放射剂量。不同剂量水平的局部控制和生存率相似。我们研究了总肿瘤体积(GTV)对结局的影响。方法和材料GTV定义为原发肿瘤和累及淋巴结的体积之和节点。分别分析了较小(≤45cm3)与较大( u3e45 cm3)肿瘤的肿瘤反应,中位生存时间(MST)和无进展生存期(PFS)。结果GTV的分布如下:≤ 161例患者中,有79例(49%)为45 cm3,82例(51%)为45 cm3。 GTV中位数为47.3 cm3。 N0状态和女性性别与更好的肿瘤反应相关。肿瘤较小(≤45cm3)的患者比肿瘤较大(≤45cm3)的患者获得更长的MST和更好的PFS(29.7 vs. 13.3个月,p <0.0001;和15.8 vs. 8.3个月,p u3c 0.0001 , 分别)。增加放射剂量对MST或PFS没有影响。在多变量分析中,只有较小的GTV是改善MST和PFS的重要预后因素(危险比[HR]为2.12,p = 0.0002; HR为2.0,p = 0.0002)。 GTV作为连续变量也与MST和PFS显着相关(HR分别为1.59,p <0.0001; HR为1.39,p <0.0001)。结论辐射剂量升高至90.3 Gy并没有导致改善了MST或PFS。淋巴结阴性患者和女性的肿瘤反应更大。 GTV升高与MST和PFS降低密切相关。未来的放射治疗试验患者可能需要根据肿瘤体积进行分层。 J.放射肿瘤生物学。物理,第70卷,第2号,第385-390页,2008年

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号